<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291941</url>
  </required_header>
  <id_info>
    <org_study_id>HN014/HBV-001 (105757)</org_study_id>
    <nct_id>NCT00291941</nct_id>
    <nct_alias>NCT00739726</nct_alias>
  </id_info>
  <brief_title>A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B.</brief_title>
  <official_title>A Multicentric, Randomised Study Comparing the Immunogenicity and Safety of Henogen's Adjuvanted Hepatitis B Vaccine Given at 0, 1, 6 Months to That of GSK Biologicals' Adjuvanted Hepatitis B Vaccine Given at 0, 1, 2, 6 Moths in Pre-Dialysis, and Dialysis Patients Who Are Hepatitis B Naive.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pre-dialysis, peritoneal dialysis and haemodialysis patients would benefit from an
      improved hepatitis B vaccine, which will elicit stronger and faster cellular and humoral
      immune responses after the primary vaccination course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants will receive either Henogen's adjuvanted hepatitis B vaccine or GSK
      Biologicals' adjuvanted hepatitis B vaccine. The study involves a total of 7 visits and blood
      samples will taken at each of these visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HBs seroprotection rate at Month 2.</measure>
    <time_frame>Month 0 and 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs antibody concentrations</measure>
    <time_frame>Months 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs seroprotection rates for all subjects.</measure>
    <time_frame>Months 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs seropositivity rates for all subjects</measure>
    <time_frame>Months 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with anti-HBs antibody concentrations equal or greater than 100 mIU/ml for all subjects.</measure>
    <time_frame>Months 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs geometric mean concentrations calculated for all subjects.</measure>
    <time_frame>Months 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-RF-1 seropositivity rates (defined as the percentage of subjects with anti-RF-1 like antibody concentrations superior or equal to 33 EU/ml, the assay cut-off) in a random subset of 50 subjects per group.</measure>
    <time_frame>Months 0 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-RF-1 like antibody geometric mean concentration in a random subset of 50 subjects per group.</measure>
    <time_frame>Month 0 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and intensity of solicited local signs and symptoms, as well as occurrence, intensity and relationship to vaccination of solicited general signs and symptoms during a 4-day follow-up (i.e. Day 0 to Day 3) after each vaccination and overall.</measure>
    <time_frame>Month 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of unsolicited symptoms reported during the 31-day (Day 0 to Day 30) follow-up period after each vaccination and overall.</measure>
    <time_frame>Month 0, 1, 2, 3, 6 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of all serious adverse events (SAEs) up to Month 7.</measure>
    <time_frame>Month 0 to 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Henogen HB vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fendrix vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Henogen HBV vaccine</intervention_name>
    <description>20µg, Month 0, 2 and 6</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FENDRIX</intervention_name>
    <description>20 µg,Months 0, 1, 2 and 6</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female subject 15 years of age or older at the time of the study entry.

          -  Written informed consent obtained from the subject/ from the parent or guardian of the
             subject.

          -  Seronegative for anti-HBs antibodies, anti-HBc antibodies and for HBsAg at screening.

          -  Pre-dialysis patients, peritoneal dialysis patients or haemodialysis patients.

          -  Non-childbearing potential female

        Exclusion Criteria:

          -  Use of any investigational or non-registered drug or vaccine within 30 days preceding
             the first dose of study vaccine, or planned use during the study period.

          -  Use of any registered vaccine within 7 days before the first dose of study vaccine.

          -  Previous vaccination against hepatitis B (whether or not the subject responded to the
             vaccine).

          -  History of hepatitis B infection.

          -  Known exposure to hepatitis B virus within 6 months.

          -  Use of immunoglobulins within six months preceding the first study vaccination.

          -  Immunosuppression caused by the administration of parenteral steroids or chemotherapy
             (oral steroids are allowed).

          -  Any confirmed or suspected human immunodeficiency virus (HIV) infection.

          -  A family history of congenital or hereditary immunodeficiency.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  Acute disease at the time of enrolment. Acute disease is defined as the presence of a
             moderate or severe illness with or without fever. All vaccines can be administered to
             persons with a minor illness such as diarrhoea, mild upper respiratory infection with
             or without low-grade febrile illness, i.e. oral/ axillary temperature &lt; 37.5°C (or 37
             °C in Czech Republic).

          -  Oral/axillary temperature superior or equal to 37.5°C (or 37 °C in Czech Republic).

          -  Pregnant or lactating female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Tielemans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ULB Hôpital Erasme Département de Néphrologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>O.L.Vrouwziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS La Madeleine ATH</name>
      <address>
        <city>ATH</city>
        <zip>7800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS Clinique Louis Caty Baudour</name>
      <address>
        <city>Baudour</city>
        <zip>7331</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ -VUB Dienst Nefrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brugmann (site V Horta) Service de néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme Département de Néphrologie</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital civil de</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ AntwerpenDienst nefrologie</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tivoli</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg Leuven Nierziekten</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Andre VESALE</name>
      <address>
        <city>Montigny le tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RHMS TournayService de néphrologie</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Heamodialysis Hospital JihlavaVrchlického</name>
      <address>
        <city>Jihlava</city>
        <zip>59586 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Liberec</name>
      <address>
        <city>Liberec</city>
        <zip>46063</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infection Diseases and AIDS Treatment ClinicUniversity Hospital with Outpatient Clinic</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>1790708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine StrahovSermirska 5</name>
      <address>
        <city>Prague</city>
        <zip>169 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk´s Hospital Socialni pece 3316/12A</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Rókus Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. István Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladár Teaching Hospital Vasvári</name>
      <address>
        <city>Győr</city>
        <zip>H-9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pest County Flór Ferenc Hospital</name>
      <address>
        <city>Kistarcsa</city>
        <zip>2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vas and Szombathely County Markusovszky Hospital</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>August 27, 2008</last_update_submitted>
  <last_update_submitted_qc>August 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Sophie Houard CSO</name_title>
    <organization>Henogen</organization>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Pre-dialysis</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

